Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Nitpicking again. Rapidly inactivate vs. essentially kills."

Is it? This is something that I don't know...maybe you can enlighten me:
Can you kill a virus? That is to say, can you cure a viral infection?

I know that the FDA is pretty sensitive about how companies use the word "cure" and I SUSPECT (but don't know) that they would want a company to show that they can actually "kill" a virus before they used that language. I SUSPECT that is why there are a lot of qualifiers attached to the term..."essentially", parens, quotation marks...in the IPIX statement.

It's one thing for a person to use such language on a message board...they have no federal agencies regulating their language and are free to avoid the qualifiers if it suits them...but I don't think it's nitpicking to point out that the Company felt like they needed to protect their use of the term "kill" the way they did.


Maybe you think this is nitpicking, too:
The language above was included in a document filed as an exhibit to an 8-K filing described as a "Press Release" and entitled Pursuing the Gold Standard in the Battle Against SARS-CoV-2 (Covid-19)".
No such press release was issued. You won't find it in the Press Release section of the Company website. It was selectively issued as a Shareholder Alert with the above title but now appears in the Updates section of the website with a different title: "Brilacidin for COVID-19: Proposed Targets and Mechanisms of Action Against SARS-CoV-2".

"So what?" you may ask.
One poster spent a lot of time pointing out that whatever that thing was, it WASN'T a press release. Ask yourself why not. Keep in mind that a press release (IPIX uses Globe Newswire) gets a MUCH wider audience than a Form 8-K exhibit and a much wider still distribution than a Shareholder Alert. Why wouldn't IPIX want the NEWS that "Brilacidin’s potent virucidal ability to rapidly inactivate (essentially “kill”) the novel coronavirus upon contact distinguishes it from all other known anti-SARS-CoV-2 drug candidates in development" to get the broadest possible distribution?

I'm sure the CEO had his reasons but they aren't apparent to me. You have any ideas?

Can Brilacidin resolve (essentially "cure") COVID-19?